Pfizer Fine Unlikely to End Off-Label Drug Marketing
Charleston Gazette › September 08, 2009
Linked as:
Summary
INDIANAPOLIS - Pfizer Inc. was slapped this week with a record $2.3 billion in fines for illegally marketing some drugs, but critics say even that eye-popping total is unlikely to end the sometimes-dangerous practice of promoting drugs for unapproved uses.
The penalty pales compared to the billion dollars or more in annual revenue that blockbuster drugs generate, and new government guidelines stir worry that the marketing of medicines for unapproved uses will become easier.See the full content of this document
Extract
Pfizer Fine Unlikely to End Off-Label Drug Marketing
"Drug companies will continue to market off-label unless the financial downside makes it u...
See the full content of this document
Sponsored links
